{"id":"intermittent-pd-1-inhibitor-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Pneumonitis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Colitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PD-1 inhibitors work by releasing the brakes on T cells that have been exhausted by chronic tumor antigen exposure. By administering these inhibitors intermittently rather than continuously, this approach aims to optimize immune activation while potentially reducing cumulative toxicity and allowing immune system recovery between treatment cycles.","oneSentence":"Intermittent PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells periodically, allowing the immune system to recognize and attack cancer cells in a cyclical dosing pattern.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:16:38.563Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic cancer (specific tumor types under investigation in phase 3 trials)"}]},"trialDetails":[{"nctId":"NCT02821013","phase":"PHASE3","title":"Duration of Anti-PD-1 Therapy in Metastatic Melanoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2016-10-31","conditions":"Unresectable/Metastatic Melanoma","enrollment":614},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT07175480","phase":"PHASE2","title":"PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk","status":"RECRUITING","sponsor":"Jinling Hospital, China","startDate":"2025-01-24","conditions":"Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC)","enrollment":30},{"nctId":"NCT04698213","phase":"PHASE2","title":"Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2020-10-07","conditions":"Renal Carcinoma Metastatic","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intermittent PD-1 inhibitor therapy","genericName":"Intermittent PD-1 inhibitor therapy","companyName":"Canadian Cancer Trials Group","companyId":"canadian-cancer-trials-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intermittent PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells periodically, allowing the immune system to recognize and attack cancer cells in a cyclical dosing pattern. Used for Advanced or metastatic cancer (specific tumor types under investigation in phase 3 trials).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}